53857-58-2

Usage

Uses

Used in Organic Synthesis:
7-Bromo-1H-indazole is used as a key intermediate in the synthesis of various organic compounds. Its unique structure allows for the creation of a wide range of chemical products, making it a valuable component in the field of organic chemistry.
Used in Pharmaceutical Industry:
7-Bromo-1H-indazole is used as a building block for the development of new pharmaceuticals. Its properties contribute to the formulation of potential drug candidates, targeting a variety of therapeutic areas.
Used in Agrochemical Industry:
7-Bromo-1H-indazole is used as a precursor in the production of agrochemicals, such as pesticides and herbicides. Its chemical structure plays a crucial role in the effectiveness of these agricultural products.
Used in Dye Industry:
7-Bromo-1H-indazole is used as a component in the manufacturing of dyes. Its presence in dye formulations contributes to the color intensity and stability of the final product.

InChI:InChI=1/C7H5BrN2/c8-6-3-1-2-5-4-9-10-7(5)6/h1-4H,(H,9,10)

Upstream product

• 53848-17-2 2-bromo-6-methylaniline 
• 845751-60-2 (2-bromo-6-methylphenyl)[(1,1-dimethylethyl)thio]diazene 
• 601-87-6 3-methyl-2-nitroaniline 
• 52414-97-8 1-bromo-3-methyl-2-nitro-benzene 
• 2942-42-9 7-Nitroindazole 
• 1829-34-1 2-hydroxy-3-bromobenzaldehyde 
• 149947-15-9 3-bromo-2-fluorobenzaldehyde 
• 593-56-6 N-methoxylamine hydrochloride 
• 116436-11-4 N-(2-bromo-6-methylphenyl)acetamide 
• 21443-96-9 1H-indazol-7-amine 
• 583-53-9 2,3-dibromobenzene 
• 679795-00-7 7-bromo-3-trimethylsilylindazole 

Downstream Products

• 701910-14-7 7-bromo-2-methyl-2H-indazole 
• 915411-02-8 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole 
• 1147015-33-5 7-bromo-1-(propane-2-yl)-1H-indazole 
• 1158680-87-5 C₉H₇BrN₂O 
• 1207969-51-4 4-bromo-2-[3-(trifluoromethyl)benzyl]-2H-indazole 
• 1248591-08-3 N-(4-methoxyphenyl)-N-methyl-1H-indazol-7-amine 
• 1207964-12-2 N-(2-hydroxyethyl)-3-{2-[3-(trifluoromethyl)benzyl]-2H-indazol-7-yl}benzamide 
• 1207969-53-6 3-{2-[3-(trifluoromethyl)benzyl]-2H-indazol-7-yl}benzoic acid 
• 1207969-52-5 Ethyl 3-[2-[3-(trifluoromethyl)benzyl]-2H-indazol-7-yl]benzoate 
• 944904-26-1 7-bromo-3-iodo-1H-indazole 
• 256228-64-5 1H-indazole-7-carbonitrile 

Relevant academic research and scientific papers

Synthesis, antifungal activity and qsar of novel pyrazole amides as succinate dehydrogenase inhibitors

We design and synthesize a series of novel pyrazole amides based on the commercialized fungicides and our previous work. The antifungal activity was tested in vitro by mycelial growth inhibition assay. The results show that all the compounds are of antifungal activities against the tested fungi at different levels. Among them, N-(2-(7-bromo-5-chloro-1H-indazol-1-yl)phenyl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide (Vk) exhibited higher antifungal activity than boscalid against two fungi. Molecular docking study revealed that the carbonyl oxygen atom of Vk forms two hydrogen bonds toward the hydroxyl hydrogens of TYR58 and TRP173.

3-(4-PIPERIDYL)-IMIDAZOLE DERIVATIVE

PROBLEM TO BE SOLVED: To provide a therapeutic agent which has strong action of adjusting α7 nicotinic acetylcholine receptor(α7 nAChR) and is used in treatment of diseases related to the cholinergic activity of the central nervous system(CNS) and/or the

A novel series of indazole-/indole-based glucagon receptor antagonists

A novel, potent series of glucagon receptor antagonists (GRAs) was discovered. These indazole- and indole-based compounds were designed on an earlier pyrazole-based GRA lead MK-0893. Structure-activity relationship (SAR) studies were focused on the C3 and C6 positions of the indazole core, as well as the benzylic position on the N-1 of indazole. Multiple potent GRAs were identified with excellent in vitro profiles and good pharmacokinetics in rat. Among them, GRA 16d was found to be orally active in blunting glucagon induced glucose excursion in an acute glucagon challenge model in glucagon receptor humanized (hGCGR) mice at 1, 3 and 10 mg/kg (mpk), and significantly lowered acute glucose levels in hGCGR ob/ob mice at 3 mpk dose.

Design and Synthesis of a Novel Series of Bicyclic Heterocycles As Potent γ-Secretase Modulators

The design and the synthesis of several chemical subclasses of imidazole containing γ-secretase modulators (GSMs) is described. Conformational restriction of pyridone 4 into bicyclic pyridone isosteres has led to compounds with high in vitro and in vivo p

NOVEL SUBSTITUTED INDAZOLE AND AZA-INDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS

The present invention is concerned with novel substituted indazole and aza-indazole derivatives of Formula (I), wherein R1, R2, R3, R4, Y, A1, A2, A3, A4, X1, X2, X3 and Het1 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

PYRROLOPYRIMIDINE ALKYNYL COMPOUNDS AND METHODS OF MAKING AND USING SAME

Provided herein are pyrrolopyrimide alkynyl compounds, and methods of making and using the same. Such compounds may be used in inflammatory or myeloproliferative disorders. The disclosure also provides for treating cancer.

Anti-cancer agents and uses thereof

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3-R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, prostate, non-small cell lung and colon. They are additionally useful in the treatment of proliferative retinopathies such as diabetic neuropathy and macular degeneration.

ANTI-CANCER AGENTS ANS USES THEREOF

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula (I): and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3 R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6- 10 carbons in the ring portion, an optionally-substituted 6- membered heteroaryl group having 1- 3 nitrogen atoms in the ring portion, an optionally-substituted 5- membered heteroaryl group having 0- 4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6- membered ring is fused either to a 5- membered ring or to a 6- membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, prostate, non-small cell lung and colon. They are additionally useful in the treatment of proliferative retinopathies such as diabetic neuropathy and macular degeneration.

4-Substituted indazoles as new inhibitors of neuronal nitric oxide synthase

A series of halo-1-H-indazoles has been synthesized and evaluated for its inhibitory activity on neuronal nitric oxide synthase. Introduction of bromine at the C4 position of the indazole ring system provided a compound almost as potent as the reference compound, that is, 7-nitroindazole (7-NI). The importance of position 4 is further demonstrated by the synthesis and pharmacological evaluation of the 4-nitroindazole which was also a potent inhibitor of NOS activity. These compounds also exhibited in vivo NOS inhibitory activity, as attested by potent antinociceptive effects following systemic administration.

Anti-cancer agents and uses thereof

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3—R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, non-small cell lung and colon.